Recalculation of conversion price for Elekta’s convertible bond due to resolution to implement Elekta share split

On September 4, 2012, Elekta’s Annual General Meeting resolved on a split of the
Company’s shares, whereby each existing share with a quotient value of SEK 2.00
will be divided into four new shares with a quotient value of SEK 0.50, without
changing the Company’s share capital. The total number of shares prior to the
split is 95,701,670, represented by 3,562,500 series A shares and 92,139,170
series B shares. Following the split, there will be 382,806,680 shares,
represented by 14,250,000 series A shares and 368,556,680 series B shares. The
record day for the split was set as September 14, 2012, assuming that the
Swedish Companies Registration Office has registered the split by that date.

Due to Elekta’s share split, the conversion price for Elekta’s convertible bond
has been recalculated. The new conversion price is SEK 97.50 (SEK 390 before
recalculation). The recalculated conversion price will be applied after the
record day, September 14, 2012, for conversions implemented following the
resolution on the share split.

******



For further information, please contact:

Johan Andersson Melbi, Investor Relations Manager, Elekta AB
Tel: +46 702 100 451, e-mail: johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 11.00 CET on September 7, 2012.


About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,300 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb.